☆ 4.1 Article

Real-world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice

CANCER REPORTS (2023)

Related references

Note: Only part of the references are listed.

Article Cell Biology

Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer

Daniel Q. Huang et al.

Summary: Liver cancer epidemiology is changing due to factors such as increasing alcohol consumption, rising obesity rates, and advancements in hepatitis B and C treatment. The Global Burden of Disease study estimated global and regional trends in liver cancer burden, revealing a 25% increase in liver cancer deaths between 2010 and 2019. Non-alcoholic steatohepatitis (NASH) and alcohol were found to have the fastest growing death rates, while hepatitis B and C showed declines. Urgent measures are needed globally to address metabolic risk factors and slow the growing burden of NASH-associated liver cancer, particularly in the Americas.

CELL METABOLISM (2022)

Add to Collection

Article Oncology

Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA

Amit G. Singal et al.

Summary: This study confirmed the clinical effectiveness of first-line lenvatinib monotherapy for unresectable hepatocellular carcinoma, providing evidence for its efficacy in real-world settings.

FUTURE ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study

Atsushi Hiraoka et al.

Summary: The study found that lenvatinib was more effective in improving progression-free survival in NAFLD/NASH-related u-HCC patients compared to viral/alcohol-related patients, with no significant difference in overall survival. Elevated ALT, modified ALBI grade 2b, elevated AFP, and NAFLD/NASH etiology were identified as significant prognostic factors for PFS.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study

Kaoru Tsuchiya et al.

Summary: The first-line systemic therapy for advanced hepatocellular carcinoma (HCC) is atezolizumab plus bevacizumab therapy, and lenvatinib has shown high response rates in real-world practice for unresectable HCC patients in Japan. Pretreatment factors like ALBI score, AFP levels, and major vascular invasion play crucial roles in treatment strategy decisions for these patients.

CANCERS (2021)

Add to Collection

Review Gastroenterology & Hepatology

Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors

Federico Pinero et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2020)

Add to Collection

Article Oncology

Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma

Susumu Maruta et al.

LIVER CANCER (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis

Jaekyung Cheon et al.

LIVER CANCER (2020)

Add to Collection

Article Oncology

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Oncology

Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment

Sadahisa Ogasawara et al.

INVESTIGATIONAL NEW DRUGS (2018)

Add to Collection

Article Medicine, General & Internal

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

G. K. Abou-Alfa et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment

Teiji Kuzuya et al.

ONCOLOGY (2018)

Add to Collection

Editorial Material Oncology

Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma

Masatoshi Kudo

LIVER CANCER (2018)

Add to Collection

Article Medicine, General & Internal

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix et al.

LANCET (2017)

Add to Collection

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.